Approval · Notice of Compliance 33943 · 2024
ACT EXEMESTANE: Notice of Compliance 33943
Issued September 5, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33943
- Date
- September 5, 2024
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to Product Monograph (to align with CRP approved PM)
- Canadian reference product
- AROMASIN (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACT EXEMESTANE | Not yet assigned | — |
Medicinal ingredients
- EXEMESTANE 25 MG per TAB